Attitudes towards COVID-19 Vaccination in Adults with Haematological Malignancies.
Richard Blennerhassett, Nada Hamad, Lisa Grech, Alastair Kwok, Tammie Choi, Cecily Forsyth, Jacqueline Jagger, Stephen Opat, Sam Harris, Bryan Anthony Chan, Mike Nguyen, Nathan Bain, Daphne Day, Eva Segelov, CANVACCS Investigators
Author Information
Richard Blennerhassett: Central Coast Haematology, North Gosford, New South Wales, Australia.
Nada Hamad: Department of Haematology, St Vincent's Hospital Sydney, Darlinghurst, New South Wales, Australia.
Lisa Grech: Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Alastair Kwok: Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia, alastair.kwok@monash.edu.
Tammie Choi: Department of Nutrition, Dietetics, and Food, Monash University, Notting Hill, Victoria, Australia.
Cecily Forsyth: Central Coast Haematology, North Gosford, New South Wales, Australia.
Jacqueline Jagger: Central Coast Haematology, North Gosford, New South Wales, Australia.
Stephen Opat: Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Sam Harris: Department of Medical Oncology, Bendigo Health, Bendigo, Victoria, Australia.
Bryan Anthony Chan: Department of Oncology, Sunshine Coast Hospital and Health Service, Birtinya, Queensland, Australia.
Mike Nguyen: Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Nathan Bain: Department of Oncology, Monash Health, Clayton, Victoria, Australia.
Daphne Day: Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
Eva Segelov: Department of Medicine, School of Clinical Sciences, Monash University, Clayton, Victoria, Australia.
INTRODUCTION: Despite people with haematological malignancies being particularly vulnerable to severe COVID-19 infection and complications, vaccine hesitancy may be a barrier to optimal vaccination. This study explored attitudes towards COVID-19 vaccination in people with haematological malignancies. METHODS: People with haematological malignancies at nine Australian health services were surveyed between June and October 2021. Sociodemographic and clinical characteristics were collected. Attitudes towards COVID-19 vaccination were explored using the Oxford COVID-19 Vaccine Hesitancy Scale, the Oxford COVID-19 Vaccine Confidence and Complacency Scale, and the Disease Influenced Vaccine Acceptance Scale-Six. Open-ended comments were qualitatively analysed. RESULTS: A total of 869 people with haematological malignancies (mean age 64.2 years, 43.6% female) participated. Most participants (85.3%) reported that they had received at least one COVID-19 vaccine dose. Participants who were younger, spoke English as a non-dominant language, and had a shorter time since diagnosis were less likely to be vaccinated. Those who were female or spoke English as their non-dominant language reported greater vaccine side-effect concerns. Younger participants reported greater concerns about the vaccine impacting their treatment. CONCLUSION: People with haematological malignancies reported high vaccine uptake; however, targeted education for specific participant groups may address vaccine hesitancy concerns, given the need for COVID-19 vaccine boosters.
